TY - JOUR
T1 - Glioblastoma multiforme recurrence
T2 - An exploratory study of 18 F FPPRGD 2 PET/CT
AU - Iagaru, Andrei
AU - Mosci, Camila
AU - Mittra, Erik
AU - Zaharchuk, Greg
AU - Fischbein, Nancy
AU - Harsh, Griffith
AU - Li, Gordon
AU - Nagpal, Seema
AU - Recht, Lawrence
AU - Gambhir, Sanjiv Sam
N1 - Publisher Copyright:
© 2015 RSNA.
PY - 2015/11
Y1 - 2015/11
N2 - Purpose: To prospectively evaluate fluorine 18 ( 18 F) 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD 2 ) positron emission tomography (PET) in patients with glioblastoma multiforme (GBM). Materials and Methods: The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient. 18 F FPPRGD 2 uptake was measured semiquantitatively in the form of maximum standardized uptake values (SUV max ) and uptake volumes before and after treatment with bevacizumab. Vital signs and laboratory results were collected before, during, and after the examinations. A nonparametric version of multivariate analysis of variance was used to assess safety outcome measures simultaneously across time points. A paired two-sample t test was performed to compare SUV max . Results: A total of 17 participants (eight men, nine women; age range, 25-65 years) were enrolled prospectively. 18 F FPPRGD 2 PET/computed tomography (CT), 18 F fluorodeoxyglucose (FDG) PET/CT, and brain magnetic resonance (MR) imaging were performed within 3 weeks, prior to the start of bevacizumab therapy. In eight of the 17 patients (47%), 18 F FPPRGD 2 PET/CT was repeated 1 week after the start of bevacizumab therapy; six patients (35%) underwent 18 F FPPRGD 2 PET/CT a third time 6 weeks after starting bevacizumab therapy. There were no changes in vital signs, electrocardiographic findings, or laboratory values that qualified as adverse events. One patient (6%) had recurrent GBM identified only on 18 F FPPRGD 2 PET images, and subsequent MR images enabled confirmation of recurrence. Of the 17 patients, 14 (82%) had recurrent GBM identified on 18 F FPPRGD 2 PET and brain MR images, while 18 F FDG PET enabled identification of recurrence in 13 (76%) patients. Two patients (12%) had no recurrent GBM. Conclusion: 18 F FPPRGD 2 is a safe PET radiopharmaceutical that has increased uptake in GBM lesions. Larger cohorts are required to confirm these preliminary findings.
AB - Purpose: To prospectively evaluate fluorine 18 ( 18 F) 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD 2 ) positron emission tomography (PET) in patients with glioblastoma multiforme (GBM). Materials and Methods: The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient. 18 F FPPRGD 2 uptake was measured semiquantitatively in the form of maximum standardized uptake values (SUV max ) and uptake volumes before and after treatment with bevacizumab. Vital signs and laboratory results were collected before, during, and after the examinations. A nonparametric version of multivariate analysis of variance was used to assess safety outcome measures simultaneously across time points. A paired two-sample t test was performed to compare SUV max . Results: A total of 17 participants (eight men, nine women; age range, 25-65 years) were enrolled prospectively. 18 F FPPRGD 2 PET/computed tomography (CT), 18 F fluorodeoxyglucose (FDG) PET/CT, and brain magnetic resonance (MR) imaging were performed within 3 weeks, prior to the start of bevacizumab therapy. In eight of the 17 patients (47%), 18 F FPPRGD 2 PET/CT was repeated 1 week after the start of bevacizumab therapy; six patients (35%) underwent 18 F FPPRGD 2 PET/CT a third time 6 weeks after starting bevacizumab therapy. There were no changes in vital signs, electrocardiographic findings, or laboratory values that qualified as adverse events. One patient (6%) had recurrent GBM identified only on 18 F FPPRGD 2 PET images, and subsequent MR images enabled confirmation of recurrence. Of the 17 patients, 14 (82%) had recurrent GBM identified on 18 F FPPRGD 2 PET and brain MR images, while 18 F FDG PET enabled identification of recurrence in 13 (76%) patients. Two patients (12%) had no recurrent GBM. Conclusion: 18 F FPPRGD 2 is a safe PET radiopharmaceutical that has increased uptake in GBM lesions. Larger cohorts are required to confirm these preliminary findings.
UR - http://www.scopus.com/inward/record.url?scp=84946049099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946049099&partnerID=8YFLogxK
U2 - 10.1148/radiol.2015141550
DO - 10.1148/radiol.2015141550
M3 - Article
C2 - 25965900
AN - SCOPUS:84946049099
SN - 0033-8419
VL - 277
SP - 497
EP - 506
JO - RADIOLOGY
JF - RADIOLOGY
IS - 2
ER -